Evidence map›Paper›PMID 41132839›Full record

ArticleActa pharmaceutica Sinica. B2025

Natural killer cell-derived granzyme B as a therapeutic target for alleviating graft injury during liver transplantation.

Kai Wang, Zhoucheng Wang, Xin Shao, Lijun Meng, Chuanjun Liu, Nasha Qiu, Wenwen Ge, Yutong Chen, Xiao Tang, Xiaodong Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kai WangGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310024, China.
Zhoucheng WangDepartment of Surgery, Zhejiang University School of Medicine, Hangzhou 310058, China.
Xin ShaoPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Lijun MengKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China.
Chuanjun LiuCollege of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
Nasha QiuKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China.
Wenwen GeDepartment of Surgery, Zhejiang University School of Medicine, Hangzhou 310058, China.
Yutong ChenThe Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Xiao TangDepartment of Surgery, Zhejiang University School of Medicine, Hangzhou 310058, China.
Xiaodong WangThe Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Zhengxing LianKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China.
Ruhong ZhouInstitute of Quantitative Biology, Shanghai Institute for Advanced Study, College of Life Sciences, Zhejiang University, Hangzhou 310027, China.
Shusen ZhengShulan Hospital Affiliated to Zhejiang Shuren University, Shulan International Medical College, Hangzhou 310015, China.
Xiaohui FanPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Xiao XuGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310024, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver transplantation (LT) has become a standard treatment for end-stage liver diseases, and graft injury is intricately associated with poor prognosis. Granzyme B (GZMB) plays a vital role in natural killer (NK) cell biology, but whether NK-derived GZMB affects graft injury remains elusive. Through the analysis of single-cell RNA-sequencing data obtained from human LT grafts and the isolation of lymphocytes from mouse livers following ischemia-reperfusion injury (IRI), we demonstrated that 2NK cells with high expression of GZMB are enriched in patients and mice. Both systemically and liver-targeted depletion of NK cells led to a notable reduction in GZMB

Indexed as

Adoptive immunotherapyGranzyme BHepatic ischemia-reperfusion injuryLiver transplantationMolecular dynamicsNanomedicineNatural killer cellsTranslational medicine

Identifiers

PMID41132839
PMCPMC12541618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.